Cardinal Health surpasses third-quarter 2025 earnings expectations and continues to display strong earnings growth with Q3 net income rising to US$506M. Despite facing tariff costs of $300M, which has led to layoffs, the healthcare firm raises its fiscal year 2025 outlook. Reflecting on insider trading, hedge fund activity, and other factors, the Q3 results highlight an upswing in the firm's financial performance. Cardinal Health has also cut employees to balance the tariff charges.
Analysts and investors anticipate continued product demand and robust Q3 earnings. The organization faces a tariff hit to the tune of up to $300 million in fiscal 2026. Its growth, despite challenges, has reluctant investors questioning their undervaluing of the Cardinal Health stock. With 84% institutional backing, the business board has endorsed strong pharma growth despite revenue concerns. The organization has also welcomed new directors with tech and healthcare expertise.
Eyeing double-digit expansion in fiscal 2026, Cardinal Health had its price target raised by various analysts, due to its strong performance. This came even as its stock fell against market gains. An analyst noted that Cardinal Health’s strong growth prospects lie in emphasizing its pharma and other segments amid tariff concerns.
Cardinal Health CAH News Analytics from Fri, 01 Nov 2024 07:00:00 GMT to Sat, 03 May 2025 12:07:35 GMT - Rating 5 - Innovation 4 - Information 7 - Rumor 2
